Close Menu

Ambry

Putting It Out There

Ambry Genetics is to make aggregated customer data publicly available, the New York Times says.

Ambry will use Progeny's software solutions and risk assessment tools to simplify client workflows.

A few more lawsuits related to Myriad Genetics' hereditary cancer testing patents are now put to bed. 

The panels diagnose genetic heart disorders and are the first step in an expansion of the number of tests the firm intends to offer. 

The court today upheld a federal district court's decision to deny a motion for a preliminary injunction by Myriad and other plaintiffs against Ambry Genetics.

NEW YORK (GenomeWeb) – Ambry Genetics and its collaborators today announced a partnership to create a hereditary cancer research registry leveraging next-generation sequencing.

NEW YORK (GenomeWeb) – Ambry Genetics has chosen Kapa Biosystems' Kapa Hyper Prep Kits for Ambry's ExomeNext and ExomeNext-Rapid exome sequencing assays, the companies said this week.

NEW YORK (GenomeWeb) — After more than three years offering clinical whole exome sequencing for pediatric and adult patients suspected of having rare genetic disorders, clinicians from Columbia University Medical Center have concluded that the approach is a feasible, useful, and timely option for

NEW YORK (GenomeWeb) – Memorial Sloan Kettering along with other academic research institutions and testing labs said they will launch a registry to collect the genomic and outcomes data of patients who have consented to prospective follow up after being tested with a multi-gene hereditary cancer

A US federal district court in Utah denied Myriad Genetics and other plaintiffs a preliminary junction that would have stopped Ambry Genetics from selling competing BRCA tests, even though the court determined this may harm Myriad's business.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.